Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohortResearch in context

Summary: Background: A safe and highly efficacious Escherichia coli-produced HPV-16/18 bivalent vaccine (Cecolin®) offers a cost-effective cervical cancer prevention measure. Here, we report data on the long-term efficacy and immunopersistence up to 10 years post-vaccination. Methods: In the Phase...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Fanghui Zhao, Qi Chen, Chao Zhao, Lingling Nie, Shangying Hu, Jian Yin, Lingxian Qiu, Zhaofeng Bi, Jiali Quan, Yufei Li, Mingzhu Li, Xun Zhang, Qinjing Pan, Caihong Li, Lidong Ke, Xiaoli Liu, Fengxian Zheng, Cuihong Dai, Zhe Wang, Xuefeng Kuang, Xinhua Jia, Yingying Su, Shoujie Huang, Qiufen Zhang, Weijin Huang, Lihui Wei, Jun Zhang, Ting Wu, Youlin Qiao, Ningshao Xia
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-08-01
Edice:	The Lancet Regional Health. Western Pacific
Témata:	Human papillomavirus vaccine Escherichia coli Long-term efficacy Immunopersistence
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S266660652500207X
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!